UK trial begins testing second-wave COVID-19 drug from US biotech Ridgeback
Exclusive: Moderna spars with U.S. scientists over COVID-19 vaccine trials
CureVac claims €75m in EU funding for mRNA COVID-19 vaccine
Gilead Licencee Gets Indian Regulatory Approval For Remdesivir Covid-19 Therapy
Assessing COVID-19’s Impact on the Biotech Industry
Sanofi, GSK Close To $624M Covid-19 Vaccine Deal With U.K. - Report
Meet Four New Virus-Fighting Technologies That Could Soon Become The Standard In Public Areas
Tesla Says It Delivered 90,650 Vehicles In Q2, Beating Estimates
Tesla to Build Mobile RNA Microfactories for CureVac’s COVID-19 Vaccine
Group testing for coronavirus – called pooled testing – could be the fastest and cheapest way to increase screening nationwide
Which drugs and therapies are proven to work, and which ones don't, for COVID-19?
CRISPR Tool, in “CARPID Diem” Spirit, Detects RNA-Protein Interactions in Living Cells
Pfizer, BioNTech Rise On ‘Positive’ Early Data Of Potential Coronavirus Vaccine
FDA Sets Bar for COVID-19 Vaccine Approval at 50 Percent Effectiveness
Researchers identify multiple molecules that shut down SARS-Cov-2 polymerase reaction
Salk researchers accelerate, expand COVID-19 research
3 "Strong Buy" Coronavirus Stocks With Massive Upside Potential
Gilead Sets Pricing For Remdesivir Vaccine At $2,340 Per Patient
NUS research team develops portable COVID-19 diagnostic system for rapid on-site testing
And another thing…on false positives
Rhinovirus rampant or testing triumphant?
Inovio adds two to the leadership team; Adrian Woolfson is out at Sangamo
Coronavirus pharma news roundup – 26/06/20
USask researchers to develop saliva-based COVID-19 home testing kit
Early childhood vaccinations might protect children from COVID-19
Researchers develop a ‘quick and easy’ COVID-19 test
Trial starts with Imperial College London coronavirus vaccine
Researchers design COVID-19 knowledge base and risk assessment tool powered by AI
A dirty job: Tracking coronavirus using human waste
Sanofi Adds COVID-19, Flu Candidates to up to $2.3B+ mRNA Vaccine Partnership with Translate Bio